Our company is led by Daniel G. Chain, PhD, who is the inventor of the patents underlying TBL-100. Dr. Chain is a seasoned biotechnology executive and scientist entrepreneur dedicated to the discovery and development of therapeutics for the treatment of neurodegenerative diseases. For more than 20 years, he has established and managed companies in the neurodegeneration field, and his patented innovations helped enable the development of several monoclonal antibodies tested in late stage clinical trials for Alzheimer’s disease and related indications by global pharmaceutical companies. In addition, Dr. Chain spearheaded the development of a clinical-stage compound currently under development for Friedreich’s Ataxia by Intellect Neurosciences, and a first-in-class clinical stage small molecule compound, itanapraced, being developed for Parkinson’s disease by CERESPIR where Dr. Chain is also engaged. Dr. Chain trained as a biochemist and molecular neurobiologist having obtained his PhD from the Weizmann Institute of Sciences in Israel and subsequently trained as a researcher at Columbia College of Physicians and Surgeons in New York.
Daniel G. Chain, PhD
John S. Gogol
Mr. John S. Gogol is an independent corporate advisor based in Gstaad, Switzerland. For more than 20 years, Mr. Gogol has assisted individual and institutional clients with identifying business opportunities for investment, merger and acquisition, especially within the pharmaceutical and financial sectors. He is a current Board member of Landmark Fiduciaire (Suisse) SA, and previously served as a director of Antares Pharma Inc..Throughout his career, Mr. Gogol has created, sponsored and managed humanitarian aid and trading companies in Europe, the Middle East and Eastern Europe. He has worked with Stokors SA, an asset management firm in Genevaand for Business International (part of The Economist Group), where he was responsible for marketing and sales in Europe, Eastern Europe and Canada.
Mr. Levinson has over 30 years of experience handling corporate and securities matters, including mergers, acquisitions and restructurings, as well as public and private debt and equity financing transactions. Mr. Levinson has represented issuers, investment bankers and independent directors in numerous proxy contests, tender offers, recapitalizations and going private transactions. His merger and acquisition work has included friendly and hostile acquisitions and dispositions in one-step and two-step transactions, including the preparation and filing of related securities registration statements and proxy statements, on both the buyer and seller side. His financing work has included bank borrowing and debt and equity issuances, as well as initial public offerings and subsequent public offerings. He has been a partner at several of New York’s most prestigious law firms, including Phillips Nizer LLP, Shereff, Friedman, Hoffman & Goodman, LLP (now known as Dechert, LLP), and Herzfeld & Rubin, P.C. He previously served as Senior Attorney in the Securities and Corporate Practices section of the Chief Counsel’s Office of the United States Office of the Comptroller of the Currency. Mr. Levinson received his B.A. degree from Yale College and his J.D. degree, with high honors, from the University of Connecticut. He also holds an M.B.A. degree from Columbia University, where he was elected to the Beta Gamma Sigma honor society. He is admitted to practice in New York, Connecticut and the District of Columbia.
Parag Saxena is the Managing Partner and CEO of Vedanta Capital and New Silk Route Partners, which he co-founded in 2006. Previously, he was CEO of INVESCO Private Capital, one of the oldest and largest venture capital firms in the US. During his 23-year tenure at INVESCO, over 300 investments were made, including, Amgen, Costco, PictureTel, Polycom, Staples and Starbucks. These investments have led to the building of companies which have created over 500,000 jobs, with an aggregate market value exceeding $500 billion.Mr. Saxena personally led more than 90 investments for INVESCO Private Capital. These investments include, Alkermes, Celgene, Genomic Health, Indigo, Masimo, Transgenomic, Xenon Pharmaceuticals, Amber Networks, ARM Holdings, MetroPCS, and Volterra. Mr. Saxena is a multi-year member of Forbes’ Midas list, which ranks the World’s best technology investors.Mr. Saxena has served on committees advising the Prime Minister of India on foreign direct investments and the Planning Commission of India on venture capital. Mr. Saxena has provided recommendations on the landscape and regulatory environment for small businesses and venture capital to representatives of the US Congress. He is also a Director of the Indian Institute of Technology, Bombay’s Heritage Fund, and a Trustee of the Bharatiya Vidya Bhavan. He is on the Advisory Board of the Center for Advanced Studies on India at the University of Pennsylvania and is on the Indian Advisory Council of Brown University.Mr. Saxena received an M.B.A. from the Wharton School of the University of Pennsylvania. He earned a B.Tech. degree from the Indian Institute of Technology, Bombay, and an M.S. in Chemical Engineering from the West Virginia College of Graduate Studies.